Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
12.86
-0.13 (-1.00%)
Jun 1, 2026, 2:44 PM EDT - Market open
Pharming Group Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 52.38 | 145.31 | 54.94 | 61.74 | 207.34 | 191.92 |
Short-Term Investments | 117.8 | 33.8 | 112.95 | 151.68 | - | - |
Cash & Short-Term Investments | 170.18 | 179.1 | 167.89 | 213.42 | 207.34 | 191.92 |
Cash Growth | 58.64% | 6.68% | -21.33% | 2.93% | 8.03% | -6.45% |
Accounts Receivable | 60.03 | 54.7 | 54.82 | 46.16 | 27.62 | 29.98 |
Inventory | 64.58 | 64.9 | 55.72 | 56.76 | 42.33 | 27.31 |
Other Current Assets | 0.73 | 0.76 | - | - | 0.21 | 0.23 |
Total Current Assets | 295.51 | 299.47 | 278.44 | 316.34 | 277.5 | 249.44 |
Net Property, Plant & Equipment | 23.1 | 23.97 | 24.13 | 33.47 | 39.15 | 33.17 |
Other Intangible Assets | 130.99 | 135.54 | 61.04 | 71.27 | 75.12 | 83.83 |
Long-Term Investments | 8.11 | 8.65 | 4.23 | 10.4 | 9.73 | 8.65 |
Other Long-Term Assets | 31.66 | 32.34 | 32.14 | 31.38 | 24.3 | 22.22 |
Total Assets | 489.37 | 499.96 | 399.99 | 462.85 | 425.8 | 397.32 |
Accounts Payable | 103.53 | 105.9 | 66.61 | 72.53 | 54.47 | 42.47 |
Current Portion of Long-Term Debt | 5.38 | 5.34 | 4.25 | 1.82 | 1.77 | 1.88 |
Current Portion of Leases | 2.77 | 3.37 | 2.95 | 3.62 | 3.47 | 2.42 |
Other Current Liabilities | 0.68 | 1.19 | - | - | - | - |
Total Current Liabilities | 112.35 | 115.79 | 73.8 | 77.97 | 59.7 | 46.77 |
Long-Term Debt | 93.39 | 92.72 | 78.15 | 136.6 | 131.62 | 139.17 |
Long-Term Leases | 14.67 | 14.35 | 26.97 | 29.51 | 29.84 | 18.46 |
Total Long-Term Liabilities | 108.06 | 107.07 | 105.12 | 166.11 | 161.46 | 157.63 |
Total Liabilities | 220.41 | 222.86 | 178.92 | 244.07 | 221.16 | 204.4 |
Common Stock | 8.07 | 8.01 | 7.77 | 7.67 | 7.51 | 7.43 |
Additional Paid-in Capital | 518.6 | 513.26 | 488.99 | 478.43 | 462.3 | 455.25 |
Accumulated Other Comprehensive Income | 23.75 | 28.82 | -0.21 | -2.06 | -8.74 | 3.4 |
Retained Earnings | -281.46 | -272.98 | -275.49 | -265.26 | -256.43 | -273.17 |
Shareholders' Equity | 268.96 | 277.1 | 221.06 | 218.78 | 204.64 | 192.92 |
Total Liabilities & Equity | 489.37 | 499.96 | 399.99 | 462.85 | 425.8 | 397.32 |
Total Debt | 116.21 | 115.78 | 112.31 | 171.55 | 166.69 | 161.93 |
Net Cash (Debt) | 53.97 | 63.33 | 55.58 | 41.88 | 40.65 | 30 |
Net Cash Growth | -14.77% | 13.94% | 32.72% | 3.03% | 35.50% | 66.77% |
Net Cash Per Share | 0.71 | 0.85 | 0.71 | 0.58 | 0.57 | 0.43 |
Book Value | 268.96 | 277.1 | 221.06 | 218.78 | 204.64 | 192.92 |
Book Value Per Share | 3.53 | 3.71 | 2.81 | 3.02 | 2.89 | 2.75 |
Tangible Book Value | 137.97 | 141.56 | 160.02 | 147.51 | 129.52 | 109.08 |
Tangible Book Value Per Share | 1.81 | 1.90 | 2.04 | 2.03 | 1.83 | 1.56 |